| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Immunology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Immunology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Immunology |
Recent Updates
Recently added Catalysts
Kymera Therapeutics, Inc.$119.35
+0.35 (+0.29%)
C 45Pipeline Score Richly Valued Biotech · Commercial
Market Cap
6.49 B
EPS
-3.57
P/E Ratio
-
Value Trade
62.57 M
SEC Financials
Q1 2026Dilution Risk
Revenue
34.37 M
R&D Expenses
98.16 M
Operating CF
-88.84 M
Total Assets
1.67 B
Total Liabilities
129.38 M
Equity
1.54 B
D/E Ratio
12,345
-6.02 %
Week
-11.61 %
1 Month
-8.33 %
3 Month
23.19 %
6 Month
77.24 %
5 Year
125.4 %
All Time
Cash Data
Cash Position
650.93 M
Monthly Burn
29.61 M
Runway
19.6 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
665.91 K
52 Week Range
28.06 - 103
% held by Insiders
11.3 %
% held by Institutions
103.49 %
Enterprise Value
5.92 B
Total Shares
31.36 M
Short %
41.9 %
Float Shares
24.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kymera Therapeutics, Inc.
538Total events
12Upcoming
77Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 12
Dec 31, 2026
T2Management Change
Jeremy Chadwick to retire as COO, remain as advisor through end of year
Event history 526
Jul 7, 2026
▲Enrollment CompleteKT-621Trial
Enrollment completed in Phase 2b study of KT-621 in atopic dermatitis
atopic dermatitissource ↗
Jul 7, 2026
◆Management ChangeCorporate
Appointment of Elizabeth Laws as SVP, Global Program Team Leader for KT-621
Q3 2026
◆Topline ReadoutKT-579Clinical Data
Phase 1 healthy volunteer data expected in second half of 2026
Healthy Volunteerssource ↗
Jun 25, 2026
▲Enrollment CompleteKT-621Trial
Completed enrollment in BROADEN2 Phase 2b trial of KT-621 in atopic dermatitis
moderate to severe atopic dermatitissource ↗
Jun 24, 2026
Jun 12, 2026
▲Oral PresentationKT-621Presentation
Oral presentation of Phase 1 data for KT-621 in healthy Japanese adults at JDA Annual Meeting
Healthy Japanese adultssource ↗
Jun 9, 2026
▲First Patient DosedSAR447971Trial
First participant dosed in Phase 1 trial of KT-485
hidradenitis suppurativasource ↗
Jun 9, 2026
▲Milestone PaymentSAR447971Corporate
$20 million milestone payment from Sanofi triggered by first patient dosing
Jun 8, 2026
Jun 3, 2026
Jun 2026
◆Poster PresentationKT-579Presentation
New data on KT-579 in lupus models at EULAR and FOCIS
lupussource ↗
Jun 2026
◆Primary CompletionKT-474Trial
Estimated primary completion for ADVANTA trial (AD) in mid-2026
Atopic dermatitissource ↗
Drug Pipeline Intelligence
C45
Pipeline Score $588M
Pipeline ValueRichly Valued
Valuation Signal6
Drugs Scored0.1x
rNPV / MCap Top 66%
Small Cap (rank 311 of 912)
Percentile RankKymera Therapeutics, Inc. carries a moderate pipeline score (45/100), with $927M risk-adjusted pipeline value, led by KT-621 in Atopic Dermatitis (Phase 2), across $95B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KT-621 Small molecule | Atopic Dermatitis | Phase 2 | NCT07217015 | 17% | $748M | ACTIVE NOT_RECRUITING | 222 | VERY_FAST | B (65) | Jun 1, 2028 | LOW_RISK | MEDIUM Jun 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
KT-621 Fast Track | chronic Type 2 inflammatory diseases | Phase 1 | 2026-06-12 | median stat6 degradation: ≥98%; enrollment: 24; dose levels: 2; treatment duration: seven days Read More | Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting Read More | |
KT-621 Fast Track | chronic Type 2 inflammatory diseases | Phase 1 | 2026-06-12 | median stat6 degradation: ≥98%; enrollment: 24; dose levels: 2; treatment duration: seven days Read More | Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting Read More | |
KT-621 Fast Track | chronic Type 2 inflammatory diseases | Phase 1 | 2026-06-12 | median stat6 degradation: ≥98%; enrollment: 24; dose levels: 2; treatment duration: seven days Read More | Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KYMR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KYMR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KYMRKymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics has appointed Dr. Elizabeth Laws as Senior Vice President and Global Program Team Leader for KT-621, a first-in-class oral STAT6 degrader. Dr. Laws, with over two decades of experience, will oversee the global development of KT-621, which is currently in Phase 2b trials for atopic dermatitis and asthma. The company anticipates data from these trials by late 2026 and mid-2027, respectively.
Read more →KYMR▲ +16.6%on this news
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Kymera Therapeutics has completed enrollment in the BROADEN2 Phase 2b trial of KT-621 for atopic dermatitis, finishing nearly six months ahead of schedule. This allows for an earlier topline data readout expected by the end of 2026. The company plans to initiate Phase 3 trials by mid-2027, following positive interest and results from earlier studies.
Read more →KYMR▲ +16.6%on this newsshared move
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera Therapeutics has appointed Felix J. Baker, Ph.D., as the new Chairman of the Board, succeeding Bruce Booth, who will remain as an Independent Director. Dr. Baker, who has been with the board since 2024, brings valuable experience in scaling innovative companies. The company aims to enhance its oral small molecule degrader pipeline to improve treatment options for patients.
Read more →KYMRKymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Kymera Therapeutics presented Phase 1 data for KT-621, an oral STAT6 degrader, at the JDA Annual Meeting. The study in healthy Japanese adults showed consistent safety and pharmacokinetic results with previous trials. KT-621 is currently undergoing parallel Phase 2b trials for atopic dermatitis and asthma, with data expected by mid-2027 and late 2027, respectively.
Read more →KYMRKymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Kymera Therapeutics has initiated a Phase 1 trial for KT-485, an oral IRAK4 degrader, with the first participant dosed. This milestone has triggered a $20 million payment from Sanofi, who is leading the trial. The study aims to evaluate the drug's safety and pharmacokinetics, with potential for significant future milestone payments.
Read more →KYMRKymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
Read more →KYMRKymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Kymera Therapeutics has appointed Penny Carlson as Senior Vice President of Development Operations. Carlson, with over 20 years of experience, will lead global clinical development operations for the company's oral immunology portfolio. This transition comes as Jeremy Chadwick retires from his role as COO but will remain as an advisor. Carlson's expertise is expected to significantly contribute to advancing Kymera's pipeline.
Read more →KYMRKymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Kymera Therapeutics will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. The event will be held in New York and will feature a live webcast available on the company's website. Kymera is focused on developing innovative oral small molecule degrader medicines for immunological diseases.
Read more →KYMRKymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Kymera Therapeutics announced significant findings from the BroADen Phase 1b clinical trial of KT-621, an oral STAT6 degrader, during presentations at the SID and ATS congresses. The data indicate robust STAT6 degradation and reductions in Type 2 inflammatory biomarkers, supporting KT-621's potential for treating atopic dermatitis and asthma. Ongoing Phase 2b trials aim to validate these findings further, with results anticipated by mid-2027.
Read more →KYMRKymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences: the Bank of America 2026 Healthcare Conference on May 12 and the RBC Capital Markets 2026 Global Healthcare Conference on May 19. Live webcasts of the presentations will be available on the company's website, with replays archived post-event. Kymera is focused on developing innovative therapies for immunological diseases.
Read more →KYMRKymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
Kymera Therapeutics has presented promising preclinical data for KT-579, a first-in-class oral IRF5 degrader, at Digestive Disease Week 2026. The data indicate that KT-579 demonstrates significant disease-modifying activity in inflammatory bowel disease (IBD) models, showing potential to outperform existing therapies. The ongoing Phase 1 trial aims to evaluate the safety and effectiveness of KT-579, with results expected in the second half of 2026. The findings suggest that KT-579 could transform treatment for complex autoimmune diseases by targeting multiple inflammatory pathways.
Read more →KYMRKymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported its Q1 2026 financial results, highlighting ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma. The FDA granted Fast Track designation for KT-621 in asthma, while the company maintains a strong cash position of $1.55 billion. Positive data from KT-621's Phase 1b trial was presented at a major dermatology conference. However, the company reported a net loss of $69.2 million for the quarter.
Read more →KYMRKymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will report its first quarter 2026 financial results on April 30, 2026. The company is known for developing oral small molecule degrader medicines aimed at immunological diseases. A video conference call and webcast will be held at 8:30 a.m. ET on the same day.
Read more →KYMRKymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
Kymera Therapeutics announced that the FDA has granted Fast Track designation for KT-621, a first-in-class oral STAT6 degrader aimed at treating moderate to severe eosinophilic asthma. This designation allows for closer collaboration with the FDA to expedite development. KT-621 is currently undergoing two Phase 2b trials, with data expected in 2027. The drug aims to provide a convenient oral alternative for asthma patients who currently have limited options.
Read more →KYMRKymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Kymera Therapeutics announced that Gilead Sciences has exercised its option to license KT-200, a novel oral CDK2 molecular glue degrader. This action triggers a $45 million milestone payment to Kymera. Gilead plans to advance KT-200 into IND-enabling studies for a potential IND filing in 2027. The drug shows promise in treating challenging cancers, particularly those with CDK2 involvement.
Read more →KYMRKymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Kymera Therapeutics presented positive results from the BroADen Phase 1b trial for KT-621, an oral STAT6 degrader for atopic dermatitis, at the AAD Annual Meeting. The trial demonstrated significant reductions in disease symptoms and biomarkers among patients. Ongoing Phase 2b trials aim to further evaluate KT-621's efficacy in atopic dermatitis and asthma, with data expected by mid-2027 and late-2027.
Read more →KYMRKymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Read more →KYMRKymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Kymera Therapeutics reported its financial results for Q4 and full year 2025, highlighting ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma, with data expected in 2027. The company also initiated a Phase 1 trial for KT-579, a novel oral degrader. Despite a net loss of $87 million in Q4, Kymera maintains a strong cash position of $1.6 billion, supporting its pipeline and growth.
Read more →KYMRKymera Therapeutics to Participate in Upcoming March Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in investor events including the UBS Biotech Summit and Jefferies Biotech on the Beach Summit in March 2026. The company focuses on developing oral small molecule degrader medicines for immunological diseases. Live webcasts of the presentations will be available on their website.
Read more →KYMRKymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Read more →KYMRKymera Therapeutics to Participate in Upcoming February Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences, including fireside chats. The company focuses on developing oral small molecule degrader medicines for immunological diseases. Live webcasts of the presentations will be available on their website, along with archived replays.
Read more →KYMRKymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics has initiated dosing in its BREADTH Phase 2b trial for KT-621, an oral STAT6 degrader aimed at treating moderate to severe eosinophilic asthma. The trial will evaluate the drug's efficacy, safety, and tolerability in approximately 264 patients over 12 weeks. Results are expected in late-2027, highlighting the company's commitment to addressing unmet needs in asthma treatment.
Read more →KYMRKymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
Kymera Therapeutics has outlined its strategic objectives for 2026, focusing on advancing its oral immunology programs. The company is currently conducting Phase 2b trials for KT-621 in atopic dermatitis and asthma, with data expected in the coming years. Additionally, KT-579 is set to enter Phase 1 trials in early 2026. Kymera's strong financial position supports its ambitious pipeline and goals.
Read more →KYMRKymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
Read more →KYMRKymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
Kymera Therapeutics has announced that the FDA granted Fast Track designation for KT-621, its first-in-class oral STAT6 degrader aimed at treating moderate to severe atopic dermatitis. The designation is supported by positive results from the BroADen Phase 1b trial. The ongoing Phase 2b trials for both atopic dermatitis and asthma are expected to yield data by mid-2027 and early 2026, respectively.
Read more →KYMRKymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Read more →KYMRKymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
Read more →KYMR▲ +41.5%on this newsshared move
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis KT-621 achieved deep STAT6 degra
Kymera Therapeutics reported positive results from the BroADen Phase 1b clinical trial for KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis. The trial demonstrated significant reductions in disease biomarkers and symptoms, including a 63% mean reduction in the Eczema Area and Severity Index (EASI). Notably, KT-621 was well-tolerated, with no serious adverse events recorded. The company plans to continue its development through ongoing Phase 2b trials, aiming to expand treatment options for Type 2 inflammatory diseases.
Read more →KYMR▲ +41.5%on this newsshared move
KT-621, Oral STAT6 Degrader, Phase 1b Results 1 Agenda Introduction Justine Koenigsberg Vice President, Investor Relations Revolutionizing Immunology with Oral Medicines Nello Mainolfi, PhD Founder, President and Chief E
Kymera Therapeutics has presented data on KT-621, an oral STAT6 degrader, which is being developed to address significant unmet needs in immunology. The company plans to initiate a Phase 2b study of KT-621 in asthma patients in Q1 2026, with Phase 2b data readouts for atopic dermatitis expected by mid-2027. There are risks associated with the uncertainty of clinical trial outcomes and the reliability of comparisons to existing therapies. Future development will focus on proving the efficacy and safety of KT-621 amidst a competitive landscape.
Read more →KYMR▲ +41.5%on this newsshared move
Kymera Therapeutics Announces Proposed Public Offering Watertown, Mass. (
Kymera Therapeutics has announced a proposed underwritten public offering of $500 million worth of shares of its common stock, with an additional option for underwriters to purchase up to $75 million more. The company plans to use the proceeds to advance its pipeline of degrader programs and for general corporate purposes. While the offering indicates growth potential, it is subject to market conditions, and investors should be aware of the associated uncertainties.
Read more →KYMR▲ +41.5%on this newsshared move
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Kymera Therapeutics will announce results from its BroADen Phase 1b clinical trial for KT-621, an oral STAT6 degrader for atopic dermatitis, on December 8, 2025. The trial aims to evaluate the drug's efficacy in patients with moderate to severe atopic dermatitis. A press release will precede a video conference call detailing the results.
Read more →KYMRKymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Read more →KYMRKymera Therapeutics to Participate in Upcoming December Investor Conferences
Kymera Therapeutics announced its participation in upcoming investor conferences, where it will engage in fireside chats. The company focuses on developing oral small molecule degrader medicines for immunological diseases and has advanced its first degrader into clinical trials. Live webcasts of the presentations will be available on their website.
Read more →KYMRKymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
Kymera Therapeutics reported its Q3 2025 financial results, highlighting significant progress in its clinical pipeline. The company completed enrollment in the KT-621 Phase 1b trial for atopic dermatitis and initiated the KT-621 BROADEN2 Phase 2b trial. Additionally, KT-579 is on track for clinical trials in early 2026, supported by a strong cash position of $979 million.
Read more →KYMRKymera Therapeutics to Participate in Upcoming November Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in upcoming investor conferences in November. The company focuses on developing oral small molecule degrader medicines for immunological diseases. Live webcasts of the presentations will be available on their website, with replays archived afterward. Kymera aims to improve patient outcomes through innovative therapies.
Read more →KYMRKymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Kymera Therapeutics, a clinical-stage biopharmaceutical company, is set to report its financial results for the third quarter of 2025 on November 4, 2025. This report will be accompanied by a video conference call scheduled for 8:30 a.m. ET, allowing stakeholders to engage directly with the company. The results will offer insights into the company's performance and developments in their innovative degrader medicines.
Read more →KYMRKymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
Kymera Therapeutics presented promising preclinical data for KT-579, an oral IRF5 degrader, at the ACR Annual Meeting. The data indicate significant disease-modifying activity in models of lupus and rheumatoid arthritis, suggesting KT-579 could offer a novel treatment option. Phase 1 testing is expected to begin in early 2026.
Read more →KYMRKymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
Kymera Therapeutics announced positive results from the Phase 1 trial of KT-621, an oral STAT6 degrader, which will be presented at the EADV and ERS Congresses. The trial demonstrated significant STAT6 degradation and favorable safety profiles. The company plans to initiate Phase 2b trials for KT-621 in atopic dermatitis and asthma in late 2025 and early 2026, respectively.
Read more →KYMR▲ +6.4%on this news
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
Kymera Therapeutics has appointed Brian Adams as Chief Legal Officer and Corporate Secretary. With extensive experience in the life sciences sector, Adams will lead the company's legal and governance functions. He succeeds Ellen Chiniara, who is retiring. Kymera aims to advance its innovative oral medicines for immunological diseases under Adams' leadership.
Read more →KYMRKymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in several upcoming investor conferences in September 2025. The events include the Citi 2025 Biopharma Back to School Conference, Wells Fargo 2025 Healthcare Conference, Morgan Stanley 23rd Annual Global Healthcare Conference, and a Stifel Virtual Immunology and Inflammation Forum. Live webcasts of these presentations will be available on the company's website, enhancing accessibility for investors.
Read more →KYMR▼ -7.2%on this news
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Read more →KYMRKymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
Read more →KYMRKymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further v
Kymera Therapeutics announced its financial results for Q2 2025, highlighting the positive outcomes of the KT-621 Phase 1 trial, which exceeded company expectations. The results showed robust target engagement and a safety profile comparable to a placebo. The company is advancing its pipeline with upcoming Phase 2b trials for KT-621 in atopic dermatitis and asthma scheduled to begin in late 2025. Additionally, Kymera entered a strategic partnership with Gilead to develop novel oral molecular glue CDK2 degraders, totaling potential payments of $750 million.
Read more →KYMRKymera Therapeutics Announces Pricing of $250 Million Public Offering
Kymera Therapeutics has announced a public offering of $250.8 million to support its clinical-stage programs focused on targeted protein degradation. The offering includes 5,044,500 shares of common stock priced at $44.00 each, alongside pre-funded warrants. The proceeds will be used to advance its drug pipeline and for general corporate purposes. The offering is expected to close on June 30, 2025.
Read more →KYMRKymera Therapeutics Announces Sanofi IRAK4 Collaboration Update Sanofi to advance Kymera s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinic
Kymera Therapeutics has announced that its collaboration with Sanofi will advance the next-generation oral IRAK4 degrader, KT-485, into clinical testing, while not progressing KT-474. KT-485, which showed improved selectivity and potency in preclinical studies, has been prioritized for development, with Sanofi exercising its right for a 50/50 profit share in the U.S. Kymera stands to gain up to $975 million through clinical milestones related to KT-485, marking a significant step forward in immunological treatments.
Read more →KYMRGilead Info Jessica Smith, Media public_affairs@gilead.com Jacquie Ross, Investors investor_relations@gilead.com Kymera Therapeutics Info Justine Koenigsberg Vice President, Investor Relations investors@kymerat
Gilead Sciences and Kymera Therapeutics announced a collaboration to develop novel oral molecular glue CDK2 degraders, aimed at improving treatment options for breast cancer and other solid tumors. The agreement allows Kymera to potentially receive up to $750 million in payments and royalties while leading the research activities. This innovative approach is designed to more precisely eliminate the CDK2 protein, a key contributor to tumor growth, rather than merely inhibiting it. While the partnership represents a significant advancement in oncology, it comes with risks related to clinical trial success and regulatory approvals.
Read more →KYMR▲ +45.5%on this news· ran to +61% by day 3
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 de
Kymera Therapeutics has announced promising results from its Phase 1 clinical trial for KT-621, a first-in-class oral STAT6 degrader. The trial showed that KT-621 exceeded its target of 90% STAT6 degradation in blood, achieving complete degradation in blood and skin at all tested higher doses. Additionally, KT-621 was well-tolerated with no serious adverse events reported. Positive Th2 biomarker improvements were observed, indicating potential efficacy in treating IL-4/IL-13-driven allergic diseases. Following these results, the company is set to initiate further trials in atopic dermatitis and asthma.
Read more →KYMRKymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
Kymera Therapeutics is set to announce the results of its Phase 1 clinical trial for KT-621, an oral small molecule degrader focused on treating Th2 inflammatory diseases, on June 2, 2025. The trial aims to evaluate the safety and tolerability in healthy volunteers. KT-621 has shown promising results in preclinical studies, suggesting it can match the efficacy of current biologic treatments. Future trials for atopic dermatitis and asthma patients are scheduled for late 2025 and early 2026, respectively.
Read more →KYMR▲ +5%on this news· ran to +51% by day 3shared move
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, has announced its participation in several investor conferences in June 2025. The company will host fireside chats at the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. Additionally, Kymera will conduct one-on-one meetings during the Wolfe Research Virtual Biotech Day. These events will be accompanied by live webcasts that will be archived on the company's website, enhancing accessibility for investors.
Read more →KYMRKymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
Kymera Therapeutics has presented promising preclinical data for KT-621, a first-in-class oral STAT6 degrader, at the American Thoracic Society International Conference. KT-621 demonstrated efficacy in reversing chronic asthma progression, showing activity comparable to dupilumab. The company plans to report Phase 1 healthy volunteer trial data in June 2025 and is advancing to Phase 2b trials in asthma and atopic dermatitis in 2025. With the potential to provide oral treatment options for various Th2 diseases, KT-621 is seen as a significant advancement in immunological therapies.
Read more →KYMRKymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed
Kymera Therapeutics has announced its financial results for Q1 2025, revealing successful progress in its clinical pipeline. The company completed the KT-621 Phase 1 trial and has begun patient dosing in the Phase 1b study for moderate to severe atopic dermatitis, with data expected by Q4 2025. Kymera's financial health remains strong with $775 million in cash, allowing operational stability until at least 2028. Additionally, the company has decided not to advance its KT-295 program, focusing resources on the promising STAT6 and new IRF5 degrader programs.
Read more →KYMRKymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
Kymera Therapeutics has announced the addition of KT-579, a new first-in-class oral degrader targeting IRF5, to its immunology pipeline. This compound shows promising preclinical efficacy and a favorable safety profile, with potential applications in treating autoimmune diseases such as rheumatoid arthritis and lupus. The drug is currently undergoing IND-enabling studies, with Phase 1 clinical trials set to commence in early 2026. Kymera's innovative approach may provide transformative treatment options for patients with chronic immuno-inflammatory conditions.
Read more →KYMRKymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
Read more →KYMR▲ +9.3%on this news
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025
Kymera Therapeutics announced a video webcast scheduled for May 9, 2025, to report its first-quarter financial results. During the event, the company will also introduce a new oral development candidate aimed at an undrugged target for multiple autoimmune and rheumatic diseases. Additionally, highlights and upcoming milestones from its immunology pipeline will be reviewed.
Read more →KYMR▲ +6%on this news· ran to +22% by day 3shared move
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
Kymera Therapeutics has announced the initiation of dosing in the BROADEN Phase 1b clinical trial for KT-621, an oral degrader of STAT6 aimed at treating moderate to severe atopic dermatitis. The company expects to report trial data in the fourth quarter of 2025, having already completed earlier dosing in healthy volunteers. There are also plans for two parallel Phase 2b trials focusing on AT and asthma to begin in late 2025 and early 2026, respectively. KT-621 represents the first targeted therapy aimed at STAT6 degradation in clinical development, with the potential to significantly improve treatment outcomes for patients with immuno-inflammatory diseases.
Read more →KYMR▲ +13.8%on this news
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
Read more →KYMR▼ -14.5%on this news
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621
Kymera Therapeutics reported its financial results for the fourth quarter and full year 2024, indicating significant ongoing investments in its clinical pipeline. The company is advancing multiple candidates including KT-621 for atopic dermatitis and KT-295 for other immunological conditions, with various trials set to begin from 2025 onwards. Despite a notable net loss and declining collaboration revenues, Kymera retains a robust cash position and anticipates a range of clinical milestones in the coming years.
Read more →KYMRKymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
Kymera Therapeutics is set to report its fourth quarter and full year 2024 financial results on February 27, 2025. The company, known for its innovative oral small molecule degrader medicines, will hold a video conference call at 8:30 a.m. ET to discuss these results. The event will allow investors and stakeholders to gain insights into the company's performance and future prospects.
Read more →KYMR▲ +7.8%on this news
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera pl
Kymera Therapeutics has outlined its key objectives and strategy for 2025, focusing on advancing its portfolio of oral immunology programs. Notably, they will continue with the Phase 1 trials for KT-621 and begin Phase 1b trials in atopic dermatitis. Additionally, Kymera plans to initiate Phase 2b trials in late 2025 for asthma. The company boasts a strong financial position, with significant cash reserves and a detailed plan for expanding its pipeline within the next two years.
Read more →KYMRKymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
Read more →KYMRKymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half
Kymera Therapeutics has announced its financial results for Q3 2024, highlighting significant progress in its immunology pipeline. The company received FDA clearance for KT-621 (STAT6) and has initiated its Phase 1 trial, with data expected in H1 2025. Despite success in immunology, Kymera will limit further development of oncology programs to partnerships, indicating a strategic shift in focus. Its strong cash position of $911 million will support ongoing and future initiatives.
Read more →KYMRKymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
Read more →KYMRKymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Read more →KYMRKymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will announce its third quarter 2024 financial results on October 31, 2024. The company specializes in targeted protein degradation and will host a conference call at 8:30 a.m. ET to discuss these results. Interested parties can participate via phone or a live webcast. A replay of the call will be available afterward.
Read more →KYMRKymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics has received FDA clearance for its Investigational New Drug application for KT-621, a novel oral STAT6 degrader. This marks a significant step for the company as KT-621 is set to enter Phase 1 clinical trials in October 2024, with results expected in the first half of 2025. The drug shows dupilumab-like activity in preclinical models and aims to provide new treatment options for atopic and allergic diseases. The Phase 1 trial will assess safety, tolerability, and pharmacokinetics compared to a placebo.
Read more →KYMRKymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
Kymera Therapeutics has presented promising preclinical data for KT-621, a selective oral STAT6 degrader, at the EADV Congress. This new compound exhibits significant degradation of STAT6, which may offer similar therapeutic benefits to dupilumab for TH2-driven allergic and atopic diseases. Clinical trials for KT-621 are set to begin in the second half of 2024, with Phase 1 data anticipated in 2025, suggesting a potentially convenient oral treatment for conditions such as atopic dermatitis and asthma. The results support the strategic importance of targeting the STAT6 pathway in addressing these prevalent diseases.
Read more →KYMRKymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Read more →KYMRKymera Therapeutics Announces Pricing of $225 Million Public Offering
Kymera Therapeutics Announces Pricing of $225 Million Public Offering
Read more →KYMRKymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development ti
Kymera Therapeutics announced its financial results for the second quarter of 2024, highlighting significant progress in its clinical programs. Sanofi plans to expand its KT-474/SAR444656 Phase 2 trials, aiming to enhance the development timeline. The company also reported advancements in several degrader programs, including the planned initiation of Phase 1 trials for STAT6 and TYK2 degraders. Overall, Kymera is well-capitalized and expects critical data releases in the coming year, reinforcing its commitment to developing treatments for severe immuno-inflammatory and oncological conditions.
Read more →KYMR▲ +7.2%on this news
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will report its second quarter 2024 financial results on August 7, 2024. The company focuses on developing small molecule medicines through targeted protein degradation (TPD). Investors can participate in a conference call at 8:30 a.m. ET on the reporting date. Additionally, a live webcast will be available on the company's website, with a replay afterwards.
Read more →KYMR▲ +23.4%on this news
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
Kymera Therapeutics has announced its participation in a fireside chat at the UBS Virtual Targeted Protein Degradation Day, scheduled for July 15, 2024. The event will be accessible via a live webcast on the company's website. This engagement underscores Kymera's advancements in targeted protein degradation technology in the biopharmaceutical space.
Read more →KYMR▲ +5.7%on this news· ran to +30% by day 1shared move
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy Watertown, Mass. (
Kymera Therapeutics has announced an expansion of its KT-474 (SAR444656) Phase 2 clinical trials for Hidradenitis Suppurativa and Atopic Dermatitis following a favorable interim review by an Independent Data Review Committee. The decision comes from collaboration with Sanofi and aims to accelerate progress towards pivotal studies for these immune-inflammatory diseases. The expansion is supported by promising preliminary safety and efficacy data, and further details about trial designs and timing for data readouts are expected to be shared soon.
Read more →KYMRKymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Kymera Therapeutics has presented promising clinical data for its STAT3 degrader KT-333 at the EHA Annual Meeting. The ongoing Phase 1 trial indicates initial proof of concept in hematological malignancies, showcasing complete responses in Hodgkin's lymphoma patients. Additionally, KT-333 has shown robust safety and tolerability, with dose escalation still underway. The company anticipates sharing more comprehensive data in late 2024 as they continue their clinical investigation into this novel treatment approach.
Read more →KYMRKymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics presented new clinical data for their MDM2 degrader, KT-253, at the ASCO Annual Meeting, demonstrating initial efficacy signs in various tumor types, including Merkel cell carcinoma and acute myeloid leukemia. The Phase 1 trial indicated that KT-253 was well-tolerated, showing potential benefits over traditional treatments by avoiding common adverse hematologic events. However, the study noted some serious adverse events, including Grade 3 hypotension and ventricular tachycardia, prompting further investigation as the trial progresses.
Read more →KYMRKymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics announced new clinical data from its ongoing Phase 1 trial of KT-253, a first-in-class MDM2 degrader. Initial results show encouraging safety and efficacy profiles, with objective responses noted in solid tumors and hematological malignancies. The data will be presented at the ASCO Annual Meeting, with a focus on the drug's pharmacodynamics and patient selection strategy. The study continues to evaluate the drug's potential for treating relapsed or refractory cancers.
Read more →KYMRKymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
Kymera Therapeutics presented promising preclinical data for KT-621, an oral STAT6 degrader, at the ATS Annual Meeting. The data showed KT-621's efficacy comparable to dupilumab in asthma models and highlighted its potential to transform treatments for TH2 respiratory diseases. The company plans to initiate Phase 1 trials in late 2024, with results expected by early 2025.
Read more →KYMR▼ -8.5%on this news
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Kymera Therapeutics announced new Phase 1 clinical data for KT-333, a STAT3 degrader, to be presented at the upcoming EHA Annual Meeting. The results indicate significant clinical responses in patients with hematological malignancies and solid tumors, showcasing the drug's potential efficacy and safety profile. Two complete responses and several partial responses were reported among specific patient groups, while notable target degradation and pathway inhibition were achieved. However, the study noted some dose-limiting toxicities at higher doses, highlighting the need for ongoing evaluation.
Read more →KYMRKymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621
Kymera Therapeutics has released its financial results for Q1 2024, indicating positive growth with $745 million in cash. The company is advancing its clinical pipeline, with ongoing Phase 2 trials for KT-474 and upcoming Phase 1 trials for KT-621 and KT-294. Data from these trials is expected in the near future, particularly focused on conditions like atopic dermatitis and inflammatory diseases. Overall, Kymera is well-capitalized to pursue its ambitious research agenda in the fight against immuno-inflammatory disorders.
Read more →KYMR▼ -5.3%on this news
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
Kymera Therapeutics, a clinical-stage biopharmaceutical company, has announced that it will report its first quarter 2024 financial results on May 2, 2024. The company specializes in targeted protein degradation and will host a conference call at 8:30 a.m. ET for stakeholders. Interested parties can access the call via phone or through a live webcast on the company's website. A replay of the webcast will also be available after the event.
Read more →KYMRKymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Read more →KYMRKymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
Kymera Therapeutics presented promising preclinical data for its oral degraders of STAT6 (KT-621) and TYK2 (KT-294) at the American Academy of Dermatology Annual Meeting. The findings indicate that KT-621 effectively degrades STAT6, demonstrating superior potency compared to existing treatments for atopic dermatitis. Meanwhile, KT-294 has shown potential for treating various immune-inflammatory diseases. Both drugs are expected to enter Phase 1 trials in 2024 and 2025, respectively.
Read more →KYMRKymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT
Kymera Therapeutics announced its fourth-quarter and full-year 2023 financial results, highlighting advancements in its drug development pipeline, particularly the KT-474 program entering Phase 2 trials for hidradenitis suppurativa and atopic dermatitis. The company reported strong revenues from recent collaborations, including a significant milestone achieved with Sanofi. With a strong cash position of $745 million, Kymera aims to advance its innovative therapies, including future Phase 1 trials for KT-621 and KT-294, expected in 2024 and 2025, respectively. The progress and financing positioning are promising, but rising R&D costs and long timelines for data release could present challenges.
Read more →KYMRKymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will disclose its fourth quarter and full year 2023 financial results on February 22, 2024. The company will host a conference call at 8:30 a.m. ET to discuss the results. Interested parties can join the call through a designated phone number or via a live webcast on the company's website.
Read more →KYMRKymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York on February 7, 2024. This event highlights Kymera's advancements in targeted protein degradation technologies. A live webcast of the discussion will be available, along with an archived replay post-event, enhancing investor accessibility to company updates.
Read more →KYMR▲ +7.8%on this news
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kymera Therapeutics has successfully completed its upsized public offering, raising $275 million by selling 3,884,158 shares of common stock. The offering included a full exercise of the underwriters' option to purchase additional shares, resulting in gross proceeds of approximately $316.2 million. The securities were offered under an effective shelf registration statement filed with the SEC. Kymera's work in targeted protein degradation positions it at the forefront of developing new therapies for cancer and immunological diseases.
Read more →KYMR▲ +7.8%on this news
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
Read more →KYMRKymera Therapeutics Announces Pricing of $275 Million Public Offering
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
Read more →KYMR▲ +18.9%on this newsshared move
IMMUNOLOGY R&D DAY
Kymera Therapeutics hosted an Immunology R&D Day, outlining their progress in developing first-in-class oral degraders like KT-474 and KT-621. The presentation emphasized the company's innovative approach to targeted protein degradation with a focus on previously undrugged targets. Despite positive advancements, the event also acknowledged the risks and uncertainties inherent in the clinical trial process and the company's future operational plans. Overall, Kymera aims to revolutionize immunology through novel therapies and intends to advance its clinical pipeline significantly over the next few years.
Read more →KYMR▲ +18.9%on this newsshared move
R&D Day Highlights Kymera s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases Company s focus on advancing first-in-class
Kymera Therapeutics has outlined its immunology strategy and emerging pipeline during its recent R&D Day. The company is focusing on the development of novel oral degraders, including KT-621 and KT-294, aimed at treating immuno-inflammatory diseases. Both candidates are expected to enter clinical trials in the coming years, highlighting their potential to compete with existing biologic therapies. Kymera believes its unique approach to targeted protein degradation could transform treatment options for patients with autoimmune conditions.
Read more →KYMRKymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
Kymera Therapeutics, a clinical-stage biopharmaceutical company, is set to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The company's Founder, President, and CEO, Nello Mainolfi, will discuss the organization's progress and expected milestones for the upcoming year. The presentation will be accessible via a live webcast, with a replay available for 30 days following the event.
Read more →KYMR▲ +7.3%on this news
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Kymera Therapeutics will host a virtual Immunology R&D Day on January 4, 2024, focusing on its innovative immunology programs. The event will present new target disclosures, supporting preclinical data, and clinical study initiation timelines. Kymera's efforts center around targeted protein degradation to develop therapies for immune-inflammatory diseases and cancers. Interested parties can access the webcast via the company's website, with a replay available post-event.
Read more →KYMR▼ -5.3%on this newsshared move
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
Kymera Therapeutics presented interim results from its Phase 1 clinical trial of KT-333, a STAT3 degrader, at the ASH Annual Meeting. The drug showed early signs of antitumor activity in various malignancies, including cutaneous T-cell lymphoma and Hodgkin's lymphoma, and was generally well-tolerated. Dose escalation continues, with the trial demonstrating promising results in STAT3 knockdown and immunomodulatory effects. However, there were dose-limiting toxicities in some patients, indicating challenges that may affect future phases of the trial.
Read more →KYMR▲ +7.2%on this newsshared move
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Read more →KYMRKymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
Kymera Therapeutics announced the publication of Phase 1 trial results for KT-474 (SAR444656), a novel IRAK4 degrader, in Nature Medicine. The study confirmed the drug's ability to induce significant IRAK4 degradation and showed a favorable safety profile in both healthy volunteers and patients with Hidradenitis Suppurativa and Atopic Dermatitis. Encouraging signs of reduced disease burden and symptoms were noted, and Kymera's partner Sanofi is conducting ongoing Phase 2 trials. This marks a significant advancement in targeted protein degradation aimed at immune-inflammatory diseases.
Read more →KYMRKymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting Abstract released today highlights safety, pharmacodynamic and clinical response data collected t
Kymera Therapeutics announced that it will present new clinical data from the Phase 1 trial of its STAT3 degrader, KT-333, at the ASH Annual Meeting in December 2023. The data includes safety, pharmacokinetic, pharmacodynamic, and clinical response results collected through July 10, 2023. Preliminary findings suggest early signs of antitumor activity in some patients, particularly those with relapsed or refractory lymphomas and certain solid tumors. Additional data following the abstract cut-off will also be showcased, reinforcing the therapeutic potential of targeted protein degradation.
Read more →KYMRKymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from
Kymera Therapeutics reported its financial results for Q3 2023 and announced the first patient was dosed in the Phase 2 HS clinical trial for KT-474/SAR444656, generating a $40 million milestone payment from Sanofi. The company also highlighted promising anti-tumor activity from its KT-333 and KT-253 programs. Despite some setbacks, including the discontinuation of KT-413, Kymera is focusing its resources on its immunology pipeline, which will be discussed in detail during its upcoming R&D Day. The company maintains a strong cash position of $435 million, ensuring its financial stability through mid-2026.
Read more →KYMRKymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
Read more →KYMRKymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
Kymera Therapeutics, a clinical-stage biopharmaceutical company, is set to report its third quarter 2023 financial results on November 2, 2023. During this time, a conference call will be held to discuss these results and offer insights into the company's advancements in targeted protein degradation therapies. Kymera's pipeline includes drug candidates aimed at treating immune-inflammatory diseases, hematologic malignancies, and solid tumors. The release includes forward-looking statements that reflect management's expectations and associated risks in the preclinical and clinical development processes.
Read more →KYMRKymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
Kymera Therapeutics has presented promising preclinical data on its MDM2 degrader KT-253, showcasing significant efficacy in treating Acute Myeloid Leukemia (AML) and Merkel Cell Carcinoma (MCC). The data reveals that KT-253 exhibits a 200-fold greater potency in inhibiting growth in p53 wild-type cancer cell lines compared to existing MDM2 small molecule inhibitors. Additionally, KT-253 demonstrated effective activity when combined with venetoclax in a resistant AML model. The company is moving forward with a Phase 1 trial and plans to disclose further results later this year.
Read more →KYMRKymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
Kymera Therapeutics has been granted Fast Track designation by the U.S. FDA for its investigational drug KT-333, aimed at treating relapsed/refractory cutaneous T-cell lymphoma and peripheral T-cell lymphoma. This designation could accelerate KT-333's development process, allowing for frequent interactions with the FDA and potential expedited approval. The Phase 1 clinical trial is currently underway, with an update on KT-333's efficacy expected in the fourth quarter of 2023. Additionally, KT-333 seeks to address the challenges posed by the STAT3 protein, which has been difficult to target with traditional therapies.
Read more →KYMR▲ +11.1%on this news
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 trials for both hidradenitis suppurativa (HS) and atopic dermatitis (AD) planned to star
Kymera Therapeutics has announced its financial results for the second quarter of 2023, reporting a cash balance of approximately $472 million that will support ongoing developments through mid-2025. The company is advancing its drug candidates with Phase 2 trials for KT-474 expected to begin in the fourth quarter, while updates on its oncology programs are anticipated later this year. Despite a reported net loss of $38.8 million, recent positive clinical data and the appointment of new executives signal continued progress in its innovative drug development strategy.
Read more →KYMRKymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
Kymera Therapeutics, Inc. is set to report its second quarter 2023 financial results on August 3, 2023, and will host a conference call the same day at 8:30 a.m. ET. The biopharmaceutical company focuses on targeted protein degradation through its innovative Pegasus platform, which develops drugs to address various diseases. The firm aims to advance its therapies targeting specific pathways linked to immune-inflammatory diseases and cancers. However, caution is advised due to potential risks affecting the timelines and outcomes of its clinical and preclinical programs.
Read more →KYMRKymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
Kymera Therapeutics has been granted FDA orphan drug designation for KT-253, a novel MDM2 degrader aimed at treating Acute Myeloid Leukemia (AML). This designation acknowledges KT-253's potential to address a crucial cancer mechanism that is difficult to target with traditional medicines. Early studies suggest that KT-253 can effectively induce cancer cell death by overcoming the MDM2 feedback loop. The ongoing Phase 1 clinical trial aims to evaluate the drug's safety and efficacy in patients with high-grade myeloid malignancies, including AML.
Read more →KYMRKymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
Kymera Therapeutics provided an update on its clinical trials for KT-333 and KT-413, showing promising results from Phase 1 dose escalation studies. Both candidates demonstrated significant target knockdown without any dose limiting toxicities. KT-333 is designed to target STAT3 in various cancers, while KT-413 targets IRAK4 and IMiD substrates for MYD88-mutant B-cell malignancies. The company plans to present more data on KT-333 at the International Conference on Malignant Lymphoma in June 2023.
Read more →KYMRKymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
Kymera Therapeutics has announced positive interim clinical data from its Phase 1 trials for KT-333 and KT-413, presented at the International Conference on Malignant Lymphoma. Both programs show substantial target knockdown with no observed dose limiting toxicities. Updated results from the trials are scheduled to be released in tandem with a poster presentation at the conference. The focus of KT-333 is on STAT3-dependent cancers while KT-413 targets MYD88-mutant B-cell malignancies, indicating a broad therapeutic reach.
Read more →KYMRKymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
Kymera Therapeutics presented promising preclinical data on KT-253, a selective MDM2 degrader, at the European Hematology Association Congress. The data revealed that KT-253 achieved over 90% MDM2 degradation in tumors within one hour, leading to significant activation of the p53 pathway and rapid cancer cell death. This contrasts with lower dosages of KT-253 and existing small molecule inhibitors, which showed only modest efficacy. The findings highlight KT-253's potential for enhanced therapeutic profiles in treating leukemias, with ongoing clinical trials set to evaluate its safety and effectiveness.
Read more →KYMRKymera Therapeutics to Participate in Upcoming June Investor Conference
Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 14, 2023. The event will feature a live webcast of a fireside chat with the management team. Kymera specializes in targeted protein degradation and has developed a powerful drug discovery platform to address challenging disease targets. The company aims to deliver effective treatments for immune-inflammatory diseases, hematologic malignancies, and solid tumors through its innovative pipeline.
Read more →KYMRKymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer Watertown, Mass. (
Kymera Therapeutics has appointed Jeremy Chadwick, Ph.D., as its new Chief Operating Officer. Dr. Chadwick brings a wealth of experience from previous roles at Takeda Pharmaceuticals and Shire Pharmaceuticals, where he led global development operations. He will be integral to Kymera's strategies aimed at maximizing the impact of its expanding pipeline, focusing on targeted protein degradation to develop novel small molecule medicines. This leadership change comes at a time when Kymera is actively progressing multiple clinical programs in immunology and oncology.
Read more →KYMRKymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
Kymera Therapeutics has initiated dosing in a Phase 1 clinical trial for its investigational MDM2 degrader, KT-253, aimed at treating relapsed or refractory high-grade myeloid malignancies, acute lymphocytic leukemia (ALL), and solid tumors. The trial will assess the safety, tolerability, and clinical activity of KT-253, providing an opportunity for enhanced efficacy compared to existing treatments. Initial data on safety and pharmacodynamics are anticipated in the latter half of 2023, representing a step forward in targeted protein degradation therapies.
Read more →KYMRKymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
Kymera Therapeutics presented promising Phase 1 clinical data for KT-474 at the EADV Symposium, indicating significant IRAK4 degradation and anti-inflammatory effects in patients with hidradenitis suppurativa and atopic dermatitis. The drug demonstrated a favorable safety profile and notable clinical activity, with responses showing competitiveness against current treatment options. Following this data, Sanofi is set to begin Phase 2 trials of KT-474, marking a critical advancement for the company's development pipeline in addressing unmet needs in inflammatory diseases.
Read more →KYMR▼ -15.1%on this news
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023; Kymera to
Kymera Therapeutics reported its first quarter 2023 financial results, highlighting significant advancements in its clinical programs, including the initiation of a Phase 1 trial for KT-253, a new MDM2 degrader. The company also plans to present clinical data for its other programs at upcoming scientific meetings. With a cash runway extending into late 2025, Kymera is well-positioned to continue developing its targeted protein degradation therapies. The firm is focusing heavily on immunology and anticipates multiple data milestones throughout the year.
Read more →KYMRKymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report first quarter 2023 financial re
Read more →KYMR▲ +5.2%on this news
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials
Kymera Therapeutics reported its financial results for Q4 and full year 2022, highlighting substantial advancements in its clinical development programs. The company plans to initiate a Phase 2 trial of its IRAK4 degrader KT-474 in partnership with Sanofi and is moving forward with ongoing Phase 1 trials for other degrader candidates. With a strong year-end cash position of $560 million, Kymera is poised to continue investing in its pipeline and pursuing its strategic objectives for 2023. Upcoming clinical data and new leadership appointments are expected to bolster the company's growth trajectory.
Read more →KYMRKymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
WATERTOWN, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report fourth quarter and full year 202
Read more →KYMR▲ +9.1%on this news· ran to +28% by day 3
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
Kymera Therapeutics outlined its strategic goals for 2023, focusing on its advancement in targeted protein degradation therapies. The company reported successful Phase 1 trial results for its lead program KT-474, and plans to advance several other candidates in its oncology pipeline. With approximately $560 million in cash, Kymera expects to fund operations through 2025, facilitating the development of innovative therapies for inflammatory diseases and cancer. Key objectives for the year include progressing KT-474 into Phase 2 trials and expanding its discovery pipeline.
Read more →KYMRKymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Ell
Read more →KYMRKymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at
Read more →KYMR▲ +14.6%on this news
KT-474 HS and AD Clinical Data and Oncology Pipeline Update C o m p a n y W e b c a s t
C o m p a n y W e b c a s t December 14, 2022 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include informat
Read more →KYMR▲ +14.6%on this news
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi s Decision to Advance KT-474 into Phase 2 Clinical Trials KT-474 Phase 1 clinical data in HS and AD pa
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi s Decision to Advance KT-474 into Phase 2 Clinical Trials KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and ac
Read more →KYMR▲ +8.1%on this newsshared move
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
Read more →KYMRKymera Therapeutics Provides Webcast Information for December 14 Investor Event
WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today shared webcast information for the vir
Read more →KYMR▲ +7.5%on this news
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update Completed patient cohort portion (Part C) of the IRAK4 degrader KT-474 Phase 1 trial Patient data from KT-474 and clinical
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update Completed patient cohort portion (Part C) of the IRAK4 degrader KT-474 Phase 1 trial Patient data from KT-474 and clinical oncology pipeline to be presented in December, 2022 Rai
Read more →KYMR▲ +7.5%on this news
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Victor Sa
Read more →KYMRKymera Therapeutics to Report Third Quarter 2022 Results on November 3
WATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report third quarter 2022 financial res
Read more →KYMR▲ +5.8%on this news· ran to +30% by day 3
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and K
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1 dose escalation KT-253 has completed IN
Read more →KYMRKymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma
WATERTOWN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug
Read more →KYMR▼ -9%on this news
Kymera Therapeutics to Participate in Upcoming September Conferences
WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Found
Read more →KYMR▲ +10%on this news
Kymera Announces $150 Million Private Placement Equity Financing Watertown, Mass. (
Kymera Announces $150 Million Private Placement Equity Financing Watertown, Mass. (August 19, 2022) Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medic
Read more →KYMRKymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1
Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMi
Read more →KYMRKymera Therapeutics to Report Second Quarter 2022 Results on August 9
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2022 financial re
Read more →KYMRKymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan
WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Mor
Read more →KYMRKymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413
Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413
Read more →KYMRKymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis
Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis
Read more →KYMRKymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug
Read more →KYMRKymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinica
Read more →KYMR▼ -9.2%on this news
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune diseases in a manner superior to kinase inhibitors -Findings support further expl
Read more →KYMR▼ -24%on this news· ran to -42% by day 3shared move
KYMERA THERAPEUTICS, INC. Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months Ended
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitor
Read more →KYMR▼ -24%on this news· ran to -42% by day 3shared move
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs Pre-clinic
Read more →KYMRKymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will repor
Read more →KYMRKymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Read more →KYMR▲ +9.4%on this news
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 deg
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of mul
Read more →KYMRKymera Therapeutics to Participate in Upcoming January and February Investor Conferences
WATERTOWN, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will partic
Read more →KYMRKymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors
WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of John Mara
Read more →KYMRKymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company
Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company
Read more →KYMRKymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Read more →KYMR▼ -10%on this news
Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day Multiple Ascending Do
Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near
Read more →KYMRKymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
Two presentations demonstrated Kymera’s STAT3 degraders can reduce STAT3 expression, modify STAT3-dependent signaling, and suppress the growth of tumors in multiple preclinical models of lymphoma and solid tumors WATERTOWN, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kymera Therape
Read more →KYMRKymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations
WATERTOWN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Vijay Sab
Read more →KYMRKymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Read more →KYMRKymera Therapeutics to Host Virtual R&D Day on December 16, 2021
WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D D
Read more →KYMRKymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data f
Read more →KYMRKymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending D
Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up t
Read more →KYMRKymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will
Read more →KYMR▲ +7.1%on this newsshared move
Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will partic
Read more →KYMRKymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy
Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Mean IRAK4 degradation of up to 96% in PBMC and up to 97%
Read more →KYMRKymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th
WATERTOWN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will
Read more →KYMRKymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit
WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will
Read more →KYMRKymera Therapeutics to Present at Upcoming September Investor Conferences
WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will prese
Read more →KYMRKymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474
Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism Recently initiat
Read more →KYMRKymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality
WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen We
Read more →KYMR▼ -5.7%on this news
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
Data demonstrate Kymera’s ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtypes with aberrant STAT3 activation Kymera anticipates IND submission for STAT3
Read more →KYMRKymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized u
Read more →KYMRKymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Read more →KYMRKymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism KT-474 has achieved and exceeded Phase 1 target degradation of 85% withi
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with
Read more →KYMRKymera Therapeutics Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that it has commenced an und
Read more →KYMRKymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer
WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elaine Ca
Read more →KYMRKymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models
Data presented at the 16th ICML Meeting demonstrate KT-413’s potent antitumor activity as a monotherapy compared to a clinically active IRAK4 kinase inhibitor or a latest generation IMiD in MYD88-mutant mouse xenograft model KT-413 shows synergistic activity in driving deep tumo
Read more →KYMRKymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting
Data demonstrate KT-413’s potential as a monotherapy and in combination with rituximab or BTK inhibitors, with potent antitumor activity in multiple xenograft models of MYD88MT DLBCL WATERTOWN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a
Read more →KYMRKymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will partic
Read more →KYMRKymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase
Novel E3 ligase identified by Kymera’s Whole-Body Atlas is expressed in selected tissues while broadly expressed in cancer cells Novel STAT3 degrader enabled by PegasusTM platform, and based on identified novel ligase, demonstrates proof-of-concept degradation across multiple in
Read more →KYMRKymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting
Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting
Read more →KYMRKymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biolo
Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021 Oncology degrader programs KT-413 and K
Read more →KYMRKymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology
WATERTOWN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Juliet Wil
Read more →KYMRKymera Therapeutics to Present at Upcoming May Investor Conferences
WATERTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present
Read more →KYMRKymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting
WATERTOWN, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract
Read more →KYMRKymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual Meeting
Data provide further evidence for the central role of IRAK4 in inflammation in hidradenitis suppurativa and support both the degrader rationale for targeting IRAK4 and KT-474 development KT-474 is in Phase 1 clinical development as a first-in-class oral IRAK4 degrader for the tr
Read more →KYMRKymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company
Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company
Read more →KYMRKymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021
Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021
Read more →KYMRKymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting
WATERTOWN, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstra
Read more →KYMRKymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors
WATERTOWN, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elena Ri
Read more →KYMRKymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update Initiated Phase 1 first-in-human dosing of KT-474, a first-in-class oral IRAK4 degrader to treat immune-inf
Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update Initiated Phase 1 first-in-human dosing of KT-474, a first-in-class oral IRAK4 degrader to treat immune-inflammatory diseases Declared KT-333 as STAT3 development c
Read more →KYMRKymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases KT-474 is the first IRAK4 degrader, and first heterobifunctional
Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to
Read more →KYMRKymera Therapeutics to Present at Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in upcomi
Read more →KYMRKymera Therapeutics to Present at Upcoming February Investor Conferences
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcomi
Read more →KYMRKymera Therapeutics Strengthens Leadership with Key Appointments and Promotions
WATERTOWN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Ashwin Gollerkeri, MD,
Read more →KYMRKymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company Company plans Phase 1 trial initiations across three novel degrader programs by end
Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company Company plans Phase 1 trial initiations across three novel degrader programs by end of 2021 Initiation of the single ascending dose portion o
Read more →KYMRKymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtua
Read more →KYMRKymera Therapeutics Announces Key Leadership Appointments
WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the appointments of William Leong, PhD,
Read more →KYMRKymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data
Read more →KYMRKymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference
WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural
Read more →KYMRKymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural
Read more →KYMRKymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized in
Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sano
Read more →KYMRKymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today announced the company will present new preclinical
Read more →KYMRKymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit
WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual
Read more →KYMRKymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa
Data to be presented at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) Results support clinical development of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS) and other IL-1R/TLR-driven autoimmune and inflammatory diseases, with Phase 1 tri
Read more →KYMRKymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
WATERTOWN, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natura
Read more →KYMRKymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors
WATERTOWN, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natura
Read more →KYMRKymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer
WATERTOWN, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural
Read more →KYMRKymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
Read more →KYMRKymera Therapeutics Announces Pricing of Upsized Initial Public Offering
Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering
Read more →KYMRKymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients
Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients
Read more →KYMRKymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
Read more →KYMRKymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis
Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis
Read more →KYMRKymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
Read more →KYMRKymera Therapeutics to Present Preclinical Data on its First-in-Class Selective and Potent Oral IRAK4 Degraders in Cutaneous Inflammation
Kymera Therapeutics to Present Preclinical Data on its First-in-Class Selective and Potent Oral IRAK4 Degraders in Cutaneous Inflammation
Read more →KYMRKymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer
Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer
Read more →KYMRKymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors
Kymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors
Read more →KYMRKymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Read more →KYMRKymera Therapeutics is Named one of the FierceBiotech's "Fierce 15" Companies of 2019
Kymera Therapeutics is Named one of the FierceBiotech's "Fierce 15" Companies of 2019
Read more →KYMRKymera Therapeutics Announces Leadership Transitions
Kymera Therapeutics Announces Leadership Transitions
Read more →KYMRKymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting
Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting
Read more →KYMRKymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic
Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic
Read more →KYMRKymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma
Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma
Read more →KYMRKymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Read more →KYMRKymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality
Kymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality
Read more →KYMRKymera Therapeutics Appoints Industry Veteran Mark E. Nuttall, Ph.D., as Chief Business Officer
Kymera Therapeutics Appoints Industry Veteran Mark E. Nuttall, Ph.D., as Chief Business Officer
Read more →KYMRKymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
Read more →Competitive Position
How KYMR ranks across every disease it competes inCompetitive Position is a premium feature
See how KYMR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial